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Abstract: Pseudotyped viruses (PVs) produced by co-transfecting cells with plasmids expressing
lentiviral core proteins and viral envelope proteins are potentially powerful tools for studying various
aspects of equine influenza virus (EIV) biology. The aim of this study was to optimise production
of equine influenza PVs. Co-transfection of the HAT protease to activate the haemagglutinin (HA)
yielded a higher titre PV than TMPRSS2 with the HA from A/equine/Richmond/1/2007 (H3N8),
whereas for A/equine/Newmarket/79 (H3N8), both proteases resulted in equivalent titres. TMPRSS4
was ineffective with the HA of either strain. There was also an inverse relationship between the
amount of protease-expression plasmids and the PV titre obtained. Interestingly, the PV titre obtained
by co-transfection of a plasmid encoding the cognate N8 NA was not as high as that generated by
the addition of exogenous neuraminidase (NA) from Clostridium perfringens to allow the release
of nascent PV particles. Finally, initial characterisation of the reliability of PV neutralisation tests
(PVNTs) demonstrated good intra-laboratory repeatability. In conclusion, we have demonstrated that
equine influenza PV production can be readily optimised to provide a flexible tool for studying EIV.
Keywords: equine influenza; pseudotyped virus; neutralisation assay
1. Introduction
Pseudotyped viruses (PVs) are increasingly being used to study a wide range of aspects of
virus biology such as receptor binding, antiviral screening, vaccine evaluation, and seroepidemiology
(reviewed in [1]). A typical approach for generating PVs is to co-transfect ‘producer’ cells with plasmids
expressing (i) the envelope protein of a virus of interest; (ii) proteins of a ‘core’ virus, often a retrovirus;
and (iii) a reporter transgene. The envelope protein enables the virus to enter ‘target’ cells permissive
to the virus of interest. During cell transduction, the reporter transgene becomes integrated into the
genome of the cell (e.g., via lentivirus vector components) and is expressed, permitting quantification.
Influenza A viruses express two surface glycoproteins; haemagglutinin (HA) and neuraminidase
(NA). The HA mediates binding to receptors on host cells prior to internalisation of the virus and
is a major target of virus neutralising antibodies. In order for influenza virus particles to become
infectious, the newly synthesised HA polyprotein (HA0) has to undergo precise protease-mediated
cleavage into two subunits (HA1 and HA2). This event exposes a ’fusion peptide’ crucial for endosomal
membrane fusion (reviewed in [2]). In nature, this virion activation is performed by intracellular
enzymes. For most influenza A subtypes, including the equine H3N8 subtype, this cleavage relies on
trypsin or trypsin-like proteases such as Transmembrane Protease Serine S1 member (TMPRSS2 or
epitheliasin) or Human Airway Trypsin-like protease (HAT or TMPRSS11D) [3]. Therefore, to generate
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infective influenza PV particles, co-transfection of a fourth plasmid expressing protease is required
(reviewed in [1]).
Accumulation of amino acid changes in the HA by a process known as antigenic drift means that
antibodies raised by exposure to an earlier strain (either through infection or vaccination) may no
longer be fully protective against a newer strain. Thus, both human and equine influenza virus (EIV)
vaccine strains are updated regularly, albeit more frequently for human influenza. Analysis of the
serological response to vaccination with updated vaccines is an important component of the process
for updating vaccines. Although neutralisation tests are generally regarded as the gold standard
for measuring antibody titres, the haemagglutination inhibition (HI) test remains the mainstay of
human influenza vaccine evaluation. However, the single radial haemolysis (SRH) assay is more
widely used to evaluate equine influenza vaccines as SRH levels correlate with protective efficacy
of vaccines (reviewed in [4]). We previously demonstrated a 65% correlation between the results of
a neutralisation test using an EIV PV and an SRH assay, with the pseudotyped virus neutralisation
test (PVNT) appearing slightly more sensitive [5]. However, the PV used only expressed the EIV
HA, and a recent study highlighted the importance of the antibody response to NA, measured by a
neuraminidase inhibition test, in determining protection against infection for human influenza [6].
The NA protein is essential for release of nascent virus particles; therefore, in order to harvest
HA-pseudotyped virus particles from cell culture media during production, it is necessary to provide
NA. Typically, exogenous NA, derived from commercially purified sources (e.g., Clostridium perfringens)
is added to the cell culture medium after plasmid-transfection. However, influenza PVs can
be generated by incorporating NA-expressing plasmids in the co-transfection procedure, thereby
producing particles with both HA and NA on their surface [7–12].
In this study, we sought to optimise production of PVs by first employing different proteases with
the particular aim of maximizing titre to enable large-scale studies to be performed using a single PV
batch. We also generated a PV co-expressing the EIV H3 HA and N8 NA from the same strain and
compared the titre obtained with that obtained by providing exogenous NA. Finally, we performed
some initial characterisation of intra-laboratory repeatability of the PVNT.
2. Results
2.1. The Effect of Different Proteases on Equine Influenza H3 PV Titre
Figure 1 shows the relative titres of PVs generated for two strains of equine influenza
(A/equine/Newmarket/1979 and A/equine/Richmond/1/2007) using different quantities of
TMPRSS2, TMPRSS4, and HAT (TMPRSS11D) protease plasmids. In all cases, the highest titre
was achieved using the lowest amount of protease plasmid (125 ng per transfection). There was no
significant difference in titre obtained using 125 ng of the TMPRSS4 plasmid and the negative control
in which no protease was provided (p > 0.05), suggesting that TMPRSS4 does not cleave the equine H3
HA. In contrast, 125 ng of the TMPRSS2 and HAT plasmids resulted in high PV titres (>1× 108 Relative
Luminescence Units/RLU) for both H3 strains. For Richmond/2007, HAT yielded a significantly
higher titre PV than TMPRSS2 (p = 0.042). However, there was no significant difference in PV titre
using HAT or TMPRSS2 for the Newmarket/79 strain (p = 0.217).
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Figure 1. Titres obtained after transduction of 293T target cells with pseudotyped viruses produced 
via co-transfection of three different protease-expressing plasmid vectors (TMPRSS2, TMPRSS4, 
HAT) using a range of protease plasmid masses for two strains: (a) A/equine/Newmarket/1979 
(H3N8); (b) A/equine/Richmond/1/2007 (H3N8). Controls had no protease-expressing plasmid (Δ 
protease) or no HA plasmid (ΔHA) added during transfection. Titres are expressed as mean relative 
luminescence units (RLU) per mL with error bars indicating the standard error of the mean. 
Statistically significant differences were calculated using an unpaired t-test and indicated by * (p < 
0.05). 
2.2. Influence of Source of Neuraminidase on PV Titre 
The titre of PVs obtained using a standard production protocol in which exogenous (Clostridium 
perfringens) NA is added was compared with the titre obtained with the incorporation of influenza 
Figure 1. Titres obtained after transduction of 293T target cells with pseudotyped viruses produced
via co-transfection of three different protease-expressing plasmid vectors (TMPRSS2, TMPRSS4, HAT)
using a range of protease plasmid masses for two strains: (a) A/equine/Newmarket/1979 (H3N8);
(b) A/equine/Richmond/1/2007 (H3N8). Controls had no protease-expressing plasmid (∆ protease) or
no HA plasmid (∆HA) added during transfection. Titres are expressed as mean relative luminescence
units (RLU) per mL with error bars indica ing the standard error of the mean. Statistically significant
differences were calculated using an unpaired t-test and indicated by * (p < 0.05).
2.2. Influence of Source of Neuraminidase on PV Titre
The titre of PVs obtained using a standard pr ction pr t col in which x genous (Clostridium
perfringens) NA is added was compared with t e titre obtained wit t corporation of influenza NA
proteins into PV particles (Figure 2). The titre was similar (around 105 RLU/mL) for negative controls
with no NA provided (∆NA) or no surface protein provided (∆NA/HA). Addition of exogenous NA
resulted in a significantly higher titre PV than the negative controls (p = 0.001), demonstrating that
NA is essential for release of PV particles from producer cells. Providing NA of the N8 subtype by
co-transfecting plasmid resulted in a high titre PV. Interestingly, the PV with N8 NA from the same
virus strain as the HA was significantly higher than the Delta NA control, but was lower in titre than
the PV produced with exogenous NA.
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Figure 2. Titres of influenza A/equine/Richmond/1/2007 (H3N8) pseudotyped virus generated by co-
transfection with plasmids expressing HA and N8 or by addition of an exogenous source of NA 
(exNA) 24 h post-transfection. Negative controls had H3 HA but no NA added (ΔNA) or neither NA 
or HA added (ΔHA/NA). Titres are expressed in relative luminescence units (RLU) per mL. Error bars 
show standard error of the mean of 8 replicates. The statistically significant difference (Mann–
Whitney test) between mean RLU/mL of N8 plasmid and the addition of exNA is indicated by *** (p 
< 0.001). 
2.3. Repeatability of Pseudotyped Virus Neutralisation Tests (PVNTs) 
Using a positive control serum sample and a PV expressing the HA of A/equine/Richmond/07 
(H3N8), PVNTs were performed on four independent occasions (Figure 3). One-way ANOVA of the 
antibody titres expressed as IC50 (the reciprocal of serum dilution required for 50% PV neutralisation) 
revealed no significant differences between the repeats (p = 0.318). 
Figure 2. Titres of influenza A/equine/Richmond 1/2007 (H3N8) pseu otyped virus generated by
co-transfection with plasmids expressing HA and 8 or by addition of an exogenous source of NA
(exNA) 24 h post-transfection. Negative controls had H3 HA but no NA added (∆NA) or neither NA
or HA added (∆HA/NA). Titres are expressed in relative luminescence units (RLU) per mL. Error bars
show standard error of the mean of 8 replicates. The statistically significant differenc (Mann–Whitney
test) between mean RLU/mL of N8 plasmid and the addition of exNA is indicated by *** (p < 0.001).
2.3. Repeatability of Pseudotyped Virus Neutralisation Tests (PVNTs)
Using a positive control s rum sample a a PV expressing the HA of A/equine/Ric mond/07
(H3N8), PVNTs were performed on four independent occasions (Figure 3). One-way ANOVA of the
antibody titres expressed as IC50 (the reciprocal of serum dilution required for 50% PV neutralisation)
revealed no significant differences between the repeats (p = 0.318).Pathogens 2016, 5, 68 5 of 8 
 
 
Figure 3. Neutralisation titres (50% inhibitory concentration, IC50) obtained using a positive control 
serum in four independent PVNTs using a PV expressing A/equine/Richmond/1/2007 (H3N8) HA 
(produced with an endogenous HAT protease-encoding plasmid and an exogenous source of NA). 
The PV RLU input ranged from 1.83 to 3.43 × 105, and the serum dilution range was 1:800 to 
1:6,553,600. Individual data points represent the IC50 calculated from each of the 5 (or 4) internal PVNT 
repeats. Horizontal line indicates mean IC50 and whiskers represent the standard error of the mean. 
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would reduce the necessity to use different batches of PV within a single study. Our results indicated 
that human HAT and TMPRSS2 proteases can efficiently cleave both equine influenza H3 strain HAs 
tested. Higher titres of the Richmond/07 PV were obtained using HAT than with TMPRSS2 while 
titres obtained with Newmarket/79 were equivalent using HAT or TMPRSS2. The use of TMPRSS2 
to successfully generate PVs expressing HA from various subtypes has been previously reported 
[13,14], and TMPRSS2 was used to generate the first reported equine influenza PV [5]. The HAT 
protease has also been used previously to generate PVs expressing human H3, H1, and H5 [14]. 
However, the titre of equine H3 PVs generated using TMPRSS4 was no better than the negative 
control lacking protease. Chaipan et al. (2009) demonstrated that TMPRSS4 could be used to produce 
a PV bearing the A/South Carolina/1/1918 (H1N1) pandemic strain HA, using the same expression 
plasmid used in this study [15]. The HA cleavage sites of the H1 HA from the 1918 strain and both 
equine H3 HAs used in the current study are monobasic (Q-X-R), specifically QIR in the case of both 
equine H3 strains. However, it is possible that amino acid changes in the vicinity of the cleavage site 
may influence the ability of different proteases to recognise and cleave the HA from different virus 
subtypes or strains. 
Although optimisation of the HA and core plasmids is extensively reported (reviewed in [1]), 
there is an absence of published work describing the impact of varying the amounts of protease used 
during PV production. An inverse correlation between the amount of protease-expressing plasmid 
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serum in four independent PVNTs using a PV expressing A/equine/Richmond/1/2007 (H3N8) HA
(produced with an endogenous HAT protease-encodi g plasmi and a xogenous source of NA).
The PV RLU input ranged from 1.83 to 3.43× 105, and the seru dilution range was 1:800 to 1:6,553,600.
Individual data points represent the IC50 calculated from each of the 5 (or 4) internal PVNT repeats.
Horizontal line indicates mean IC50 and whiskers represent the standard error of the mean.
3. Discussion
Pseudotyped virus neutralisation tests are being increasingly used to measure antibody responses
to influenza A viruses for exp rimental st dies. However, if t ey a e to be more widely adopted,
including outside the research laboratory, PVNTs will have to demonstrate at least equivalent utility
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to established assays. As variability can occur when the reagents used change from assay to assay,
we investigated whether different proteases to cleave, and thus activate the HA, could be used to
optimise the titre of PV produced for larger or high-throughput serological studies. This would
reduce the necessity to use different batches of PV within a single study. Our results indicated that
human HAT and TMPRSS2 proteases can efficiently cleave both equine influenza H3 strain HAs
tested. Higher titres of the Richmond/07 PV were obtained using HAT than with TMPRSS2 while
titres obtained with Newmarket/79 were equivalent using HAT or TMPRSS2. The use of TMPRSS2 to
successfully generate PVs expressing HA from various subtypes has been previously reported [13,14],
and TMPRSS2 was used to generate the first reported equine influenza PV [5]. The HAT protease
has also been used previously to generate PVs expressing human H3, H1, and H5 [14]. However,
the titre of equine H3 PVs generated using TMPRSS4 was no better than the negative control lacking
protease. Chaipan et al. (2009) demonstrated that TMPRSS4 could be used to produce a PV bearing
the A/South Carolina/1/1918 (H1N1) pandemic strain HA, using the same expression plasmid used
in this study [15]. The HA cleavage sites of the H1 HA from the 1918 strain and both equine H3 HAs
used in the current study are monobasic (Q-X-R), specifically QIR in the case of both equine H3 strains.
However, it is possible that amino acid changes in the vicinity of the cleavage site may influence the
ability of different proteases to recognise and cleave the HA from different virus subtypes or strains.
Although optimisation of the HA and core plasmids is extensively reported (reviewed in [1]),
there is an absence of published work describing the impact of varying the amounts of protease used
during PV production. An inverse correlation between the amount of protease-expressing plasmid
used and the titre of PV obtained was demonstrated here. Thus, it is clear that plasmid titration is
essential to maximise the concentration of activated PV particles.
We next investigated the impact on PV titre of employing a different source of NA. In the standard
protocol, an exogenous source of NA (commercially purified Clostridium perfringens enzyme) is used,
but NA can be provided by inclusion of NA-expressing plasmids during co-transfection. Although it
would have been more cost-effective to use an NA expression plasmid, use of exogenous NA was more
efficient. However, it may be desirable to generate a PV expressing both HA and NA. For example, a
comparison of neutralisation titres obtained with a PV expressing HA alone and one expressing both
HA and NA would enable the measurement of the contribution of anti-neuraminidase antibodies to a
protective immune response. For example, NA-inhibiting antibody titres could be measured by adding
serial dilutions of serum to producer cells after transfection and measuring the reduction in titre of
released PV in a similar approach to that used to determine neuraminidase inhibitor activity [16].
It is believed that only viruses with balanced enzymatic activity of the NA and HA binding
avidity can survive in nature and that the HA and NA undergo compensatory co-evolution during
antigenic drift in order to maintain this balance [17,18]. Nonetheless, different combinations of HA and
NA may differ in their compatibility. A study using reverse genetics to generate reassortant viruses
found that a reassortant with an H9N2 background and avian N3 NA replicated more efficiently
in mice than the parental H9N2 virus but less efficiently in chickens, suggesting that an H9N3
reassortant might more readily become established in a mammalian host [19]. The N3 NA also had
a significantly higher enzymatic activity than the N2 NA. In another study, supplying endogenous
N1, N3, N4, and N9 NA (as co-transfected plasmids), all resulted in high titre PV production with the
A/equine/Richmond/1/2007 HA (data not shown) with the N1 NA resulting in a PV titre equivalent
to using exogenous NA. These results emphasise that whether it is preferable to provide neuraminidase
activity exogenously or endogenously should be assessed on a case-by-case basis, depending on the
application for which the PV is required.
Another point to consider is that the sialic acid receptor composition on the human-derived
HEK293T/17 cells, used as the target cell line for the PVNT, is likely to be different to that of equine
cells. An equine dermal cell line kindly provided by Dr. Pablo Murcia (University of Glasgow) was
trialled in a PV titration assay, but the production titre was reduced compared to HEK293T/17 cells
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(data not shown). Equine cell lines are not easy to obtain commercially; isolation of equine influenza
viruses is typically done in embryonated hens’ eggs.
Finally, in a separate study, we tested the repeatability of the PVNT. Several studies have compared
PVNT with other serological assays [1], but there is a paucity of similar published studies directly
examining robustness of the PVNT. Four independent experiments were conducted on different
days using the same batch of an A/equine/Richmond/07 (H3N8) HA-only PV. Results revealed no
statistically significant differences in IC50 values between the tests, demonstrating intra-laboratory
consistency of the assay when performed by the same researcher. However, further studies are required,
including an inter-laboratory assessment of the reproducibility of the assay. This testing is necessary
if the PVNT is to become more widely adopted for equine influenza scientific work (e.g., studies of
the impact of changes in the HA on antigenicity) and clinical applications such as equine vaccine
evaluation, using a safe, reliable, flexible, biologically relevant system.
4. Materials and Methods
4.1. Generation of H3 Pseudotyped Viruses
The full-length HA genes of A/equine/Newmarket/1979 (H3N8) and A/equine/Richmond/2007
(H3N8) were kindly provided by Dr. Adam Rash and Dr. Debra Elton (Animal Health Trust,
Newmarket, UK) who PCR-amplified the HA gene using the custom primers (Invitrogen) described
in [5]. The PCR fragments were digested with restriction enzymes EcoRV/BamHI and BamHI/XhoI
(Thermo Scientific) for A/equine/Newmarket/1979 and A/equine/Richmond/2007, respectively, and
cloned into the pI.18 expression plasmid. Both gene sequences were confirmed by bidirectional custom
sequencing (GATC Biotech) using primers binding to the arms of the pI.18 vector.
Influenza pseudotyped lentivirus particles expressing the firefly luciferase reporter gene
were generated by plasmid co-transfection as previously described [5] with the following
variations. Different protease plasmids were used: pCAGGS-TMPRSS2, pCAGGS-TMPRSS4, and
pCAGGS-HAT. The HAT and TMPRSS2 proteases were kindly provided by Dr. Hans Dieter Klenk
(Philipps-Universität, Marburg, Germany) and the TMPRSS4 plasmid by Dr. Stefan Pohlmann
(Leibniz-Institut für Primatenforschung, Göttingen, Germany). Polyethylenimine (PEI) was used
as the transfection reagent. Neuraminidase was supplied either exogenously, by the addition of 1U of
soluble Clostridium perfringens NA (Sigma) 24 h after transfection, or by transfection of an additional
plasmid (pI.18) expressing the relevant viral NA. The NA gene of A/equine/Richmond/1/2007
(H3N8), GenBank accession number KF559336 was synthesised by Genscript and cloned into pUC57
before sub-cloning into pI.18 using restriction enzymes BamHI/XhoI.
4.2. Pseudotyped Virus Neutralisation Test (PVNT)
The PVs were titrated and neutralisation tests performed essentially as described previously using
positive control serum from a hyper-immunised experimental pony and negative control serum from
two influenza-naïve horses [5].
4.3. Statistical Analysis
Data were expressed as mean ± standard error of the mean. Differences between two data sets
were tested with an unpaired t-test unless normal distributions could not be assumed, in which case
the Mann–Whitney test was used. ANOVA was used to test repeated measures. p-values < 0.05
were considered statistically significant. PVNA IC50 values were calculated by normalising raw RLU
values to assay controls and performing a non-linear regression analysis using GraphPad Prism
version 7.01 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. Raw
data are available on request.
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PVNT pseudotyped virus neutralisation test
TMPRSS2/4 Transmembrane Protease Serine S1 member 2/4
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